Coeptis Therapeutics Inc Stock Price, News & Analysis

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its management will ring the Nasdaq Opening Bell on Nov. 16, 2022. CEO Dave Mehalick expressed excitement about the event, marking the completion of their business combination with Bull Horn Holdings Corp. The company aims to lead in cell therapy technologies for cancer, particularly through their SNAP-CAR platform and a new cell therapy targeting CD38-related cancers. Coeptis is also partnering with VyGen-Bio and researchers at the Karolinska Institutet to develop additional therapies and diagnostics.

Coeptis Therapeutics (NASDAQ: COEP) announced that its Scientific Advisory Board members, Hans-Gustaf Ljunggren and Evren Alici, participated in the Immuno Oncology Talks podcast discussing Natural Killer (NK) Cells. The company focuses on innovative cancer therapies, significantly featuring the CD38-GEAR-NK platform and CD38-Diagnostic tool, co-developed with VyGen-Bio and Karolinska Institutet. Company President David Mehalick highlighted the expertise of these board members as crucial in advancing Coeptis' commitment to effective cancer treatments.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced the appointment of new directors to its Board following its merger with Bull Horn Holdings. The Board has expanded to seven members, including four independent directors. Key individuals include CEO Dave Mehalick and newly appointed members with diverse expertise in business and clinical development. This restructuring aligns with the company’s focus on advancing its cell therapy technologies, such as SNAP-CAR, aimed at treating various cancers, and reflects its commitment to becoming a leader in innovative cancer treatments.

Coeptis Therapeutics has entered an exclusive license agreement with the University of Pittsburgh for the SNAP-CAR technology, allowing for a programmable CAR T cell therapy targeting multiple cancer antigens. This innovative approach aims to broaden treatment options for hematologic malignancies and solid tumors like breast and ovarian cancer. The SNAP-CAR platform is poised to enhance CAR T therapies by potentially reducing toxicity and addressing cancer relapse, marking a significant advance in Coeptis' cell therapy product portfolio.

Coeptis Therapeutics has entered into an exclusive option agreement with the University of Pittsburgh for three CAR-T technologies aimed at various cancer treatments, including breast and ovarian cancers. This agreement is a strategic move to enhance Coeptis' portfolio and follows two other significant agreements in the current quarter. The company has until October 29, 2022, to exercise the options, with potential extensions available. CEO Dave Mehalick emphasized the transformative potential these technologies hold for addressing underserved cancer types.

Coeptis Therapeutics, Inc. (OTC PINK: COEP) and Bull Horn Holdings Corp. (Nasdaq: BHSE) have announced a definitive merger agreement, with Coeptis becoming a wholly-owned subsidiary of Bull Horn. The transaction, valued at $175 million, is expected to close in Q3 2022, pending regulatory and shareholder approvals. Coeptis focuses on innovative cell therapy platforms for cancer, including CD38-GEAR-NK and CD38-Diagnostic. David Mehalick will continue as CEO, while Chris Calise joins the Board. The merged entity will be rebranded as Coeptis Therapeutics Holdings, Inc., to list under the ticker symbol 'COEP'.

Coeptis Therapeutics has entered into a strategic agreement with Statera Biopharma to acquire its toll-like receptor 5 (TLR5) agonist platform, including the clinical-stage candidate entolimod, for $6 million. The agreement is subject to further negotiation and financing conditions. Entolimod is being developed to treat acute radiation syndrome and has shown potential in treating neutropenia and anemia in cancer patients. This acquisition is expected to enhance Coeptis' pipeline and address underserved medical needs in light of the current geopolitical climate.

Coeptis Therapeutics (OTC PINK: COEP) has established a Scientific Advisory Board (SAB) to guide the development of its cancer cell therapy platforms, particularly the CD38-GEAR-NK and CD38-Diagnostic technologies. The SAB includes leading researchers from the Karolinska Institutet: Dr. Evren Alici, Dr. Hans-Gustaf Ljunggren, and Dr. Arnika Kathleen Wagner. Their expertise is expected to enhance the company's product portfolio targeting CD38-associated cancers, with an initial focus on multiple myeloma.

Coeptis Therapeutics (OTC PINK: COEP) announced on Aug. 19, 2021, its acquisition of two technology assets targeting CD38 cancers from VyGen-Bio, Inc. The assets are CD38-GEAR-NK, a cell therapy product, and CD38-Diagnostic, an in vitro diagnostic tool. This acquisition follows previous option agreements made on May 18, 2021, and aims to enhance treatment paradigms for multiple myeloma and other cancers. Coeptis plans to initiate development programs, highlighting the partnership's potential as a significant value driver for the company.